KR20210111242A - 혈액 뇌 장벽 수송을 향상시키기 위한 인간화 및 안정화된 fc5 변이체 - Google Patents

혈액 뇌 장벽 수송을 향상시키기 위한 인간화 및 안정화된 fc5 변이체 Download PDF

Info

Publication number
KR20210111242A
KR20210111242A KR1020217016206A KR20217016206A KR20210111242A KR 20210111242 A KR20210111242 A KR 20210111242A KR 1020217016206 A KR1020217016206 A KR 1020217016206A KR 20217016206 A KR20217016206 A KR 20217016206A KR 20210111242 A KR20210111242 A KR 20210111242A
Authority
KR
South Korea
Prior art keywords
seq
amino acid
variable domain
antibody variable
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020217016206A
Other languages
English (en)
Korean (ko)
Inventor
벤자민 에이 스미스
안드레아스 레만
토마스 오 카메론
알 블레이크 페핀스키
딩이 웬
그라햄 케이 파링턴
고팔란 라그후나탄
넬스 이 페더슨
다니카 스타니미로빅
트라이안 술레아
아르살란 에스 하콰니
Original Assignee
바이오젠 엠에이 인코포레이티드
내셔날 리서치 카운실 오브 캐나다
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이오젠 엠에이 인코포레이티드, 내셔날 리서치 카운실 오브 캐나다 filed Critical 바이오젠 엠에이 인코포레이티드
Publication of KR20210111242A publication Critical patent/KR20210111242A/ko
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
KR1020217016206A 2018-10-29 2019-10-28 혈액 뇌 장벽 수송을 향상시키기 위한 인간화 및 안정화된 fc5 변이체 Abandoned KR20210111242A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862751962P 2018-10-29 2018-10-29
US62/751,962 2018-10-29
PCT/US2019/058286 WO2020092202A2 (en) 2018-10-29 2019-10-28 Humanized and stabilized fc5 variants for enhancement of blood brain barrier transport

Publications (1)

Publication Number Publication Date
KR20210111242A true KR20210111242A (ko) 2021-09-10

Family

ID=68582454

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217016206A Abandoned KR20210111242A (ko) 2018-10-29 2019-10-28 혈액 뇌 장벽 수송을 향상시키기 위한 인간화 및 안정화된 fc5 변이체

Country Status (13)

Country Link
US (1) US20220089704A1 (https=)
EP (1) EP3873934A2 (https=)
JP (2) JP2022509372A (https=)
KR (1) KR20210111242A (https=)
CN (1) CN113508135A (https=)
AU (1) AU2019371814A1 (https=)
BR (1) BR112021008105A2 (https=)
CA (1) CA3117409A1 (https=)
EA (1) EA202191179A1 (https=)
IL (1) IL282677A (https=)
MA (1) MA54070A (https=)
MX (1) MX2021004772A (https=)
WO (1) WO2020092202A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
WO2022023559A1 (en) * 2020-07-31 2022-02-03 Curevac Ag Nucleic acid encoded antibody mixtures
US20250222129A1 (en) * 2022-03-21 2025-07-10 National Research Council Of Canada Lipid Based Nanoparticles for Targeted Gene Delivery to the Brain
CN116650660B (zh) * 2023-07-27 2023-11-03 上海偌妥生物科技有限公司 制备抗体偶联小分子药物的方法及其应用
CN119735674B (zh) * 2024-12-06 2026-01-16 合肥综合性国家科学中心大健康研究院 抗vmat2的抗体或其抗原结合片段及其组合物和应用

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
GB8620926D0 (en) 1986-08-29 1986-10-08 Delta Biotechnology Ltd Yeast promoter
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
CA2441903C (en) * 2000-05-26 2012-07-31 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
WO2005037867A1 (en) 2003-10-15 2005-04-28 Pdl Biopharma, Inc. ALTERATION OF Fc-FUSION PROTEIN SERUM HALF-LIVES BY MUTAGENESIS OF POSITIONS 250, 314 AND/OR 428 OF THE HEAVY CHAIN CONSTANT REGION OF IG
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
MEP35408A (en) 2005-05-27 2011-02-10 Biogen Idec Inc Tweak binding antibodies
EP3470072A1 (en) 2005-06-23 2019-04-17 Biogen MA Inc. Compositions and methods for modulation of smn2 splicing
CA2620351C (en) 2005-08-31 2015-04-21 Universite Laval Antibodies and their use in the treatment, prevention and diagnosis of a disease associated with sod1 abnormalities
US7846445B2 (en) 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
WO2008081008A1 (en) 2007-01-05 2008-07-10 University Of Zurich Method of providing disease-specific binding molecules and targets
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
JP2010536341A (ja) 2007-08-15 2010-12-02 アムニクス， インコーポレイテッド 生物学的に活性なポリペプチドの特性を改変するための組成物および方法
CA2729961C (en) * 2008-07-09 2018-05-01 Biogen Idec Ma Inc. Li113, li62 variant co2, anti-lingo antibodies
CN102317316B (zh) 2008-12-19 2014-08-13 帕尼玛制药股份公司 人抗α突触核蛋白自身抗体
JP2012515556A (ja) 2009-01-23 2012-07-12 バイオジェン・アイデック・エムエイ・インコーポレイテッド 低下したエフェクタ機能を有する安定化Ｆｃポリペプチドおよび使用方法
US8680050B2 (en) 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
ES2610356T3 (es) 2009-02-03 2017-04-27 Amunix Operating Inc. Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos
US8703717B2 (en) 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
WO2010144508A1 (en) 2009-06-08 2010-12-16 Amunix Operating Inc. Glucose-regulating polypeptides and methods of making and using same
KR101813727B1 (ko) 2009-06-08 2018-01-02 아뮤닉스 오퍼레이팅 인코포레이티드 성장 호르몬 폴리펩타이드 및 이를 제조하고 사용하는 방법
ES2699827T3 (es) 2009-06-17 2019-02-13 Biogen Ma Inc Composiciones y métodos para la modulación de corte y empalme de SMN2 en un sujeto
CA2771999A1 (en) 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor vii compositions and methods of making and using same
WO2011028344A2 (en) 2009-08-25 2011-03-10 Amunix Operating Inc. Interleukin-1 receptor antagonist compositions and methods of making and using same
EP2493921B1 (en) 2009-10-30 2018-09-26 Albumedix Ltd Albumin variants
KR20130020765A (ko) 2010-02-16 2013-02-28 메디뮨 엘엘씨 Ｈｓａ-관련 조성물 및 사용방법
NZ601117A (en) * 2010-03-03 2014-06-27 Boehringer Ingelheim Int Biparatopic abeta binding polypeptides
EP2556087A1 (en) 2010-04-09 2013-02-13 Novozymes Biopharma DK A/S Albumin derivatives and variants
US20130017997A1 (en) 2010-08-19 2013-01-17 Amunix Operating Inc. Factor VIII Compositions and Methods of Making and Using Same
CA2813493C (en) 2010-10-11 2019-07-09 University Of Zurich Human anti-tau antibodies
US20130225496A1 (en) 2010-11-01 2013-08-29 Novozymes Biopharma Dk A/S Albumin Variants
AU2011343161B2 (en) 2010-12-17 2017-02-02 Neurimmune Holding Ag Human anti-SOD1 antibodies
US9045564B2 (en) 2011-02-15 2015-06-02 Medimmune, Llc HSA-related compositions and methods of use
CN103379915A (zh) 2011-02-15 2013-10-30 米迪缪尼有限公司 Hsa相关组合物及使用方法
CA2830660A1 (en) 2011-05-05 2012-11-08 Novozymes Biopharma Dk A/S Albumin variants
SI2723379T1 (sl) 2011-06-23 2019-03-29 Biogen International Neuroscience Gmbh Molekule, ki se vežejo ma anti alfa-sinuklein
RU2654567C2 (ru) 2011-10-11 2018-05-21 Дженентек, Инк. Улучшенная сборка биспецифических антител
US9587014B2 (en) 2011-10-28 2017-03-07 Biogen International Neuroscience Gmbh TDP-43 specific binding molecules
US9676849B2 (en) * 2012-01-10 2017-06-13 Biogen Ma Inc. Enhancement of transport of therapeutic molecules across the blood brain barrier
JP6355563B2 (ja) 2012-02-27 2018-07-11 アムニクス オペレーティング インコーポレイテッド Ｘｔｅｎ共役組成物およびそれを製造する方法
NZ630542A (en) 2012-08-16 2017-06-30 Ipierian Inc Methods of treating a tauopathy
CA2896066C (en) 2012-12-21 2022-07-12 Biogen Ma Inc. Human anti-tau antibodies
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
US20160033523A1 (en) 2013-02-16 2016-02-04 Novozymes Biopharma Dk A/S Pharmacokinetic animal model
KR102042174B1 (ko) * 2013-03-29 2019-11-08 삼성전자주식회사 인간화 및 친화도 성숙된 항 ｃ-Ｍｅｔ 항체 및 그의 용도
WO2014179657A1 (en) 2013-05-03 2014-11-06 Eleven Biotherapeutics, Inc. Albumin variants binding to fcrn
SG10201902850TA (en) 2014-09-30 2019-04-29 Neurimmune Holding Ag Human-derived anti-dipeptide repeats (dprs) antibody
ES2924282T3 (es) * 2014-12-19 2022-10-05 Medimmune Ltd Moléculas de transporte a través de la barrera hematoencefálica y usos de las mismas
US10654917B2 (en) * 2015-01-29 2020-05-19 Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa Antibody molecules and peptide delivery systems for use in alzheimer's disease and related disorders
WO2017106462A1 (en) 2015-12-18 2017-06-22 Biogen Ma Inc. Bispecific antibody platform
BR112019000220A2 (pt) * 2016-07-06 2019-04-24 National Research Council Of Canada anticorpos humanizados que transmigram a barreira hematoencefálica e usos dos mesmos
WO2018109663A1 (en) * 2016-12-12 2018-06-21 National Research Council Of Canada Antibody variants transmigrating the blood-brain barrier and uses thereof
WO2018138709A1 (en) * 2017-01-30 2018-08-02 National Research Council Of Canada Blood-brain barrier transmigrating compounds and uses thereof
CA3059938A1 (en) * 2017-04-14 2018-10-18 Kodiak Sciences Inc. Complement factor d antagonist antibodies and conjugates thereof

Also Published As

Publication number Publication date
JP2022509372A (ja) 2022-01-20
EA202191179A1 (ru) 2021-09-09
WO2020092202A2 (en) 2020-05-07
CA3117409A1 (en) 2020-05-07
US20220089704A1 (en) 2022-03-24
CN113508135A (zh) 2021-10-15
EP3873934A2 (en) 2021-09-08
WO2020092202A3 (en) 2020-07-23
MX2021004772A (es) 2021-08-16
MA54070A (fr) 2021-09-08
JP2024177499A (ja) 2024-12-19
IL282677A (en) 2021-06-30
BR112021008105A2 (pt) 2021-08-03
AU2019371814A1 (en) 2021-06-17
WO2020092202A9 (en) 2021-05-14

Similar Documents

Publication Publication Date Title
KR20210111242A (ko) 혈액 뇌 장벽 수송을 향상시키기 위한 인간화 및 안정화된 fc5 변이체
KR102616835B1 (ko) 개선된 혈청 알부민 결합성 면역글로불린 단일 가변 도메인
JP6993228B2 (ja) 抗トランスフェリン受容体／抗ｂａｃｅ１多重特異性抗体および使用方法
KR20190134997A (ko) 항-tau 항체 및 이의 사용 방법
JP7785669B2 (ja) Ｎ末端ｓｃＦｖ多重特異性結合分子
JP2021529796A (ja) 多特異性Ｗｎｔ代替分子及びその使用
CA2944402A1 (en) Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
TW201908342A (zh) 用於治療之藥劑、用途及方法
JP2016027801A (ja) 改良された抗血清アルブミン結合変異体
KR20260030123A (ko) 혈액 뇌 장벽을 통과하여 그라눌린을 전달하기 위한 화합물
JP2021531756A (ja) ＣＣＲ４を標的指向する改変Ｆｃ抗原結合ドメイン構築体に関する組成物および方法
US11780910B1 (en) Anti-ANGPTL3 antibodies suitable for high concentration compositions and subcutaneous administration
KR20240005823A (ko) 다중특이적 fgf21 수용체 효능제 및 그의 용도
JP2021531755A (ja) 改変されたＦｃ−抗原結合ドメイン構築物に関する組成物および方法
WO2025247301A1 (en) Novel antibodies specific for cd98 heavy chain and methods of uses thereof
EP4565608A2 (en) Pharmaceutical compositions of fusion proteins and methods of use thereof
CN119486756A (zh) 包含结合γ-δ T细胞受体的抗体的组合物
EA052560B1 (ru) Способы применения антител, распознающих тау
HK1245289B (en) Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
HK1188946A (en) A pharmaceutical composition of a complex of an anti-dig antibody and digoxigenin that is conjugated to a peptide

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PC1902 Submission of document of abandonment before decision of registration

St.27 status event code: N-1-6-B10-B11-nap-PC1902